Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Emergency Medicine

Background:

• Four-factor prothrombin complex concentrate (4F-PCC) is the standard for reversing warfarin in critical bleeding.
• Current dosing relies on weight and INR, causing delays.
• Alternative dosing strategies are being explored for efficiency and efficacy.

Purpose of the Study:

• To evaluate a pharmacist-driven, fixed-dose 4F-PCC regimen against standard dosing for warfarin reversal.
• To assess the primary outcome of achieving an INR less than two.
• To compare secondary outcomes including dose, cost, time, vitamin K use, and thrombosis incidence.

Main Methods:

• Retrospective, single-center, pre- and post-protocol analysis.
• Compared a modified fixed-dose (1500 IU) 4F-PCC regimen with weight- and INR-based dosing.
• Included 195 patients (74 pre-cohort, 121 post-cohort) with life-threatening bleeding on warfarin.

Main Results:

• Primary endpoint (INR < 2) achieved in 92% (pre) vs. 95% (post) (p=0.097).
• Significant reduction in median 4F-PCC dose and cost (p < 0.001) with the fixed-dose regimen.
• No significant difference in thromboembolic events (3 vs. 8, p=0.453).

Conclusions:

• A 1500 IU fixed-dose of 4F-PCC is effective for warfarin reversal in most patients.
• This regimen achieves target INR rapidly with reduced costs.
• The fixed-dose strategy demonstrates comparable safety to standard dosing regarding thrombotic risk.